Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Dev Dyn ; 253(3): 312-332, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37776236

ABSTRACT

INTRODUCTION: Primary cilia play pivotal roles in the patterning and morphogenesis of a wide variety of organs during mammalian development. Here we examined murine foregut septation in the cobblestone mutant, a hypomorphic allele of the gene encoding the intraflagellar transport protein IFT88, a protein essential for normal cilia function. RESULTS: We reveal a crucial role for primary cilia in foregut division, since their dramatic decrease in cilia in both the foregut endoderm and mesenchyme of mutant embryos resulted in a proximal tracheoesophageal septation defects and in the formation of distal tracheo(broncho)esophageal fistulae similar to the most common congenital tracheoesophageal malformations in humans. Interestingly, the dorsoventral patterning determining the dorsal digestive and the ventral respiratory endoderm remained intact, whereas Hedgehog signaling was aberrantly activated. CONCLUSIONS: Our results demonstrate the cobblestone mutant to represent one of the very few mouse models that display both correct endodermal dorsoventral specification but defective compartmentalization of the proximal foregut. It stands exemplary for a tracheoesophageal ciliopathy, offering the possibility to elucidate the molecular mechanisms how primary cilia orchestrate the septation process. The plethora of malformations observed in the cobblestone embryo allow for a deeper insight into a putative link between primary cilia and human VATER/VACTERL syndromes.


Subject(s)
Ciliopathies , Hedgehog Proteins , Humans , Animals , Mice , Hedgehog Proteins/genetics , Cilia , Alleles , Disease Models, Animal , Mammals
2.
BMJ Open ; 8(6): e022622, 2018 06 30.
Article in English | MEDLINE | ID: mdl-29961039

ABSTRACT

INTRODUCTION: Cardiovascular disease (CVD) mortality is higher among breast cancer survivors (BCS) who receive chemotherapy compared with those not receiving chemotherapy. Anthracycline chemotherapy is of particular concern due to anthracycline-related impairment of vascular endothelial cells and dysregulation of the extracellular matrix. One strategy proven to offset these impairments is a form of exercise known as high-intensity interval training (HIIT). HIIT improves endothelial function in non-cancer populations by decreasing oxidative stress, the main contributor to anthracycline-induced vascular dysfunction. The purpose of this pilot study is to assess the feasibility of an 8-week HIIT, as well as the HIIT effects on endothelial function and extracellular matrix remodelling, in BCS undergoing anthracycline chemotherapy. METHODS AND ANALYSIS: Thirty BCS are randomised to either HIIT, an 8-week HIIT intervention occurring three times per week (seven alternating bouts of 90% of peak power output followed by 10% peak power output), or delayed group (DEL). Feasibility of HIIT is assessed by (1) the percentage of completed exercise sessions and (2) the number of minutes of exercise completed over the course of the study. Vascular function is assessed using brachial artery flow-mediated dilation and carotid intima media thickness. Extracellular matrix remodelling is assessed by the level of matrix metalloproteinases in the plasma. A repeated-measures analysis of covariance model will be performed with group (HIIT and DEL group) and time (pre/post assessment) as independent factors. We hypothesise that HIIT will be feasible in BCS undergoing anthracycline chemotherapy, and that HIIT will improve endothelial function and extracellular matrix remodelling, compared with the DEL group. Success of this study will provide evidence of feasibility and efficacy to support a larger definitive trial which will impact cancer survivorship by decreasing anthracycline-induced vascular dysfunction, thereby benefiting cardiovascular markers that are related to CVD risk. ETHICS AND DISSEMINATION: This trial was approved by the University of Southern California Institutional Review Board (HS-15-00227). TRIAL REGISTRATION NUMBER: NCT02454777; Pre-results.


Subject(s)
Anthracyclines/administration & dosage , Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Cancer Survivors , Cardiovascular Diseases/physiopathology , Exercise Therapy/methods , High-Intensity Interval Training , Randomized Controlled Trials as Topic , Adult , Anthracyclines/adverse effects , Antineoplastic Agents/adverse effects , Breast Neoplasms/complications , Cardiac Rehabilitation/methods , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/pathology , Carotid Intima-Media Thickness , Female , Humans , Middle Aged , Physical Fitness , Pilot Projects , Regional Blood Flow , Research Design
SELECTION OF CITATIONS
SEARCH DETAIL
...